stoxline Quote Chart Rank Option Currency Glossary
  
Alterity Therapeutics Limited (ATHE)
1.94  0.03 (1.57%)    06-12 16:00
Open: 1.92
High: 1.94
Volume: 10,974
  
Pre. Close: 1.91
Low: 1.8401
Market Cap: 18(M)
Technical analysis
2024-06-12 4:20:28 PM
Short term     
Mid term     
Targets 6-month :  2.42 1-year :  2.6
Resists First :  2.07 Second :  2.23
Pivot price 1.92
Supports First :  1.83 Second :  1.52
MAs MA(5) :  1.9 MA(20) :  1.94
MA(100) :  1.97 MA(250) :  2.34
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  53.3 D(3) :  40
RSI RSI(14): 48.3
52-week High :  5.4 Low :  1.54
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ATHE ] has closed below upper band by 40.8%. Bollinger Bands are 61.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 17 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.94 - 1.95 1.95 - 1.96
Low: 1.82 - 1.83 1.83 - 1.84
Close: 1.92 - 1.94 1.94 - 1.96
Company Description

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Headline News

Thu, 23 May 2024
Alterity Therapeutics Announces Option Cessation - TipRanks.com - TipRanks

Tue, 16 Apr 2024
Alterity Therapeutics Unveils Promising Neurological Data - TipRanks.com - TipRanks

Mon, 15 Apr 2024
Alterity Therapeutics Expands Securities Quotation - TipRanks.com - TipRanks

Mon, 15 Apr 2024
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's ... - Markets Insider

Thu, 11 Apr 2024
Alterity Therapeutics Launches Exclusive Options Offer - TipRanks.com - TipRanks

Mon, 04 Dec 2023
Why Is Neurodegenerative Disease-Focused Alterity Therapeutics (ATHE) Stock Trading Over 200% Higher Toda - Benzinga

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Underperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Neutral
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 9 (M)
Shares Float 2,540 (M)
Held by Insiders 0 (%)
Held by Institutions 1 (%)
Shares Short 35 (K)
Shares Short P.Month 90 (K)
Stock Financials
EPS -1.73
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -348.4 %
Return on Assets (ttm) -29 %
Return on Equity (ttm) -53.8 %
Qtrly Rev. Growth -20.3 %
Gross Profit (p.s.) 0
Sales Per Share 0.39
EBITDA (p.s.) -1.47
Qtrly Earnings Growth 0 %
Operating Cash Flow -15 (M)
Levered Free Cash Flow -10 (M)
Stock Valuations
PE Ratio -1.13
PEG Ratio 0
Price to Book value 194
Price to Sales 4.93
Price to Cash Flow -1.16
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android